Refractory chronic GVHD (cGVHD) remains a major cause of morbidity after transplantation. Many drugs are used but there is no consensus on the standard of care. We investigated the efficacy of TLI in corticosteroid-refractory cGVHD. We analyzed retrospectively 31 patients receiving one or more TLI session for refractory cGVHD from 2000 to 2007. The main objective was to evaluate the response rate after TLI. Decreased corticosteroid doses and/or discontinued immunosuppressive agents were considered to be surrogate markers of response. All but one patient presented with severe cGVHD at the time of TLI. The median number of previous immunosuppressive treatment lines was 3 (range: 2-4). Fourteen patients (45%) achieved an objective response after TLI and 8 (25%) were cGVHD free at long-term follow-up. In all, 5 (29%) of the 17 nonresponsive patients did not show the features of progressive cGVHD and could decrease the amount of immunosuppressive drugs taken. Response after TLI significantly improved 5-year GVHD-related mortality (14% vs 42%, P ¼ 0.038) but not OS (58%vs 64% P ¼ 0.27). Regarding the promising response rate in this heavily pretreated population, we reasoned that TLI could be an alternative treatment for corticosteroid-refractory cGVHD.
INTRODUCTION
Chronic GVHD (cGVHD) is the most important and common longterm complication after transplantation. In all, 30-70% of patients undergoing allogeneic hematopoietic SCT have cGVHD. 1 Symptoms of cGVHD usually develop within the first year after transplantation, with a median time to onset of 4-6 months, but 5-10% of cases appear after 1 year. cGVHD seems to be associated with a lower rate of relapse, 2,3 but remains a major cause of longterm, non-relapse mortality. 4 The first-line therapy is often corticosteroids and/or calcineurin inhibitors. 5 However, almost half of the patients are dependent or refractory to corticosteroid treatment, leading to a poor outcome. 6 For these patients, salvage therapy is needed, but a standard treatment has not been established. 7 Use of mycophenolate mofetil 8 (MMF), tacrolimus 9 or high-dose corticosteroids 10 has been reported in several clinical trials, with a global response rate of 35-70%. More recently, novel target therapies such as rituximab 11 and imatinib 12 have been evaluated with promising results. However, series using TLI or thoracoabdominal irradiation have been reported, with interesting results. 13, 14 The aim of this study was to evaluate the efficacy of TLI as salvage treatment for corticosteroid-refractory cGVHD.
PATIENTS AND METHODS

Selection criteria
Patients were included in this retrospective analysis if they received TLI sessions to treat refractory cGVHD in our center from 2000 to 2007. We defined refractory cGVHD as progressive or persistent symptoms of cGVHD after first-line (corticosteroid therapy with 1 mg/kg/day CsA) and salvage treatments. The salvage therapies used within our institution were MMF, high-dose corticosteroid, and low-dose MTX, azathioprine or antithymocyte globulin. According to our center-specific guidelines, TLI was used as investigational treatment after failure of the therapies described above.
Conditioning regimens and stem-cell support
Patients receiving reduced-intensity conditioning or myeloablative conditioning regimens without restrictions were included. GVHD prophylaxis comprised CsA alone or with other agents such as MTX, MMF or antithymocyte globulin. Different graft sources (BM or PBSCs), donors (related or unrelated) and compatibilities (HLA 10/10 or 9/10) were used depending on hematological malignancies, conditioning regimens or the transplantation period.
Acute GVHD
Patients with acute GVHD (aGVHD) according to the Glucksberg et al. 15 classification were treated according to our institutional guidelines. Highdose corticosteroid was first-line therapy. For resistant or severe aGVHD, other immunosuppressive agents were used: MMF, MTX, anti-thymocyte globulin or CD25 Abs.
Chronic GVHD
The severity of cGVHD was scored retrospectively according to criteria set recently by the National Institutes of Health (NIH): mild, moderate and severe. 16 cGVHD occurrence was defined: as 'de novo' if there was no previous aGVHD; 'quiescent' if there was a history of responsive aGVHD; and 'progressive' if cGVHD followed active aGVHD without GVHD-free time. 17 Overlap syndrome was defined by the concomitant features of aGVHD and cGVHD. 16 Total lymphoid irradiation TLI was administered from a linear accelerator (4, 15 or 18 MV photon beam) at a single dose of 150 cGy. Irradiation comprised an supradiaphragmatic mantle field, a subdiaphragmatic field that included an inverted Y, and splenic ports encompassing all major lymphoid organs, including the thymus, spleen and lymph nodes (as used in the treatment of Hodgkin's disease).
Criteria for the therapeutic response
The efficacy of TLI was evaluated as recommended by the NIH Response Criteria Working Group Report. 18 CR indicated resolution of all reversible manifestations related to cGVHD in a specific organ. Partial response in a specific organ required X50% improvement in the scale used to measure disease manifestations related to cGVHD. The decrease in systemic immunosuppressive treatment was studied as a surrogate marker of efficacy. We considered treatment to be significantly decreased if a continuous non-corticosteroid drug was stopped (CSA, azathioprine and MMF) or if the corticosteroid dose was decreased to o0.5 mg/kg/day.
Supportive care
Patients with cGVHD received anti-infectious prophylaxis during immunosuppressive treatment in accordance with our institutional guidelines. This comprised a prophylactic dose of oral valaciclovir (500 mg Â 2/day every day), low-dose amoxicillin (500 mg Â 3/j every day), sulfamethoxazoletrimethoprime (800 mg Â 2/j, 2 days/week) and fluconazole (200 mg/day every day).
Objectives and statistical methods
The main objective was to evaluate the response rate to TLI. The secondary objectives were to evaluate the possibility of discontinuing immunosuppressive drugs, the impact of TLI timing in the therapeutic strategy, OSand GVHD-related mortality. Decrease of immunosuppressive treatment after TLI was considered to be a surrogate marker of response. We performed univariate analyses to find factors influencing the response as well as OS-and GVHD-related deaths. The Kaplan-Meier method with the log-rank test was used to estimate OS. 19 For GVHD-related mortality, the Prentice estimation and Gray test were used. Deaths from causes other than GVHD (hematological relapse or secondary cancer) were considered to be competing events for GVHD-related mortality. All survival analyses were computed on R 2.13.1 statistical software (http://www.R-project.org).
RESULTS
Thirty-one patients received one or more TLI session. The main characteristics of the patients are summarized in Table 1 . Patients were transplanted mainly with PBSCs (n ¼ 23), and had matched sibling donors (n ¼ 27). Reduced-intensity conditioning regimens were used for 21 of 31 patients, and were based mainly on fludarabine (Fludara, Bayer Santé , Puteaux, France), BU (Myleran GlaxoSmithKline, Marly-le-roi, France or BusilvexPierre Fabre, Boulogne-Billancourt, France) and rabbit anti-thymocyte globulin (ThymoglobulinGenzyme, Lyon, France). The characteristics of cGVHD are summarized in Table 2 . The median time to cGVHD development was 4.2 months (range: 2-13.7 months). cGVHD was de novo, quiescent and progressive in 3 (10%), 10 (33%) and 17 (57%) patients, respectively. One patient presented with overlapping features of aGVHD and cGVHD. In this case, the skin was involved with erythroderma and extensive sclerotic features 2 months after transplantation. Targets of cGVHD were the skin (n ¼ 22; score 3: 13; score 2: 8; score 1: 1) with eight skin sclerosis, liver (n ¼ 22; score 3: 15; score 2: 4; score 1: 3), gastrointestinal tract (n ¼ 11 score 3: 3; score 2: 7; score 1: 1), oral cavity (n ¼ 6; score 3: 1; score 2: 1; score 1: 4), lung (n ¼ 3; score 3: 1; score 2: 1; score 1: 1), joints (n ¼ 3; score 3: 0; score 2: 1; score 1: 2) and eyes (n ¼ 3; score 3: 3; score 2: 0; score 1: 0). Twenty-three (74%) patients presented with severe cGVHD according to NIH staging criteria at the first manifestation of GVHD (100% extensive regarding Seattle criteria), and all but one patient had severe cGVHD at the time of TLI. The median number of treatment lines before TLI was 3 (range: 2-4). We considered as 'early TLI' the 9 patients who received two lines before TLI and as 'late TLI' the 22 remaining patients. The median follow-up since the first TLI session was 66 months.
Response rate and TLI failure Treatment outcome is shown in Figure 1 . In all, 22 patients received only one TLI session and 9 received two TLI sessions in a median time of 4.1 months after the first session. An objective response (CR or PR) was obtained for 14 patients (45%). These responses were observed at 3 months from TLI for 13 patients and there was one late response at 6 months. Five of the fourteen who had a response received a second TLI session as consolidation treatment. They achieved sustained remission, and four of these patients had a decreased amount of immunosuppressive drugs. Eight patients obtained a sustained CR of cGVHD. There was no difference in the response rate with respect to the number of immunosuppressive treatments before TLI, with an objective response rate of 56% (5/9) and 41% (9/22) for, respectively, two lines and three or four lines before TLI (P ¼ 0.36). Among the 17 patients who did not achieve at least a PR after the first TLI session, 4 patients received a second TLI without a response. Six of the seventeen nonresponding patients (35%) did not show progressive cGVHD at the final follow-up. No side effects were noted.
Other immunosuppressive treatments As a surrogate marker of efficacy, we evaluated the reduction of use of associated immunosuppressive drugs. At 6 months after a TLI session, eight patients could significantly reduce the amount of systemic immunosuppressive treatment (26%). At the final follow-up, 13 patients (42%) were alive without recurrence of hematological disease and a decrease or discontinuation of immunosuppressive drugs. Among the eight responsive patients with long-term sustained CR of cGVHD features, six were immunosuppressive agent-free and two had reduced doses of corsticosteroid at last follow-up. Five (29%) of the seventeen nonresponsive patients did not show the features of progressive cGVHD and could discontinue the amount of immunosuppressive agent or reduce the dose of the corticosteroid.
Outcome
In total, 14 patients died, 10 from cGVHD, 2 from relapse of their hematological malignancy and 2 from a secondary cancer (1 lung cancer and 1 secondary ALL). Five-year OS as well as the prevalence of GVHD-related mortality and relapse were 60%, 29% and 12%, respectively. Response to TLI for nonresponding and responding patients decreased significantly from 42% to 14% with regard to 5-year GVHD-related mortality, respectively (P ¼ 0.038; Table 3; Figure 2a ) but 5-year OS was not improved significantly (58% vs 64% P ¼ 0.27; Table 3; Figure 2b ). Treatment lines before TLI did not influence significantly 5-year GVHD-related mortality (11% vs 38% for early and late TLI, respectively, P ¼ 0.14; Table 3 ; Figure 2c ) or 5-year OS (78% vs 51% for early and late TLI, respectively, P ¼ 0.19; Table 3 ; Figure 2d ).
Organ-specific response Skin (n ¼ 22) and hepatic (n ¼ 22) symptoms, which were the most common targets of cGVHD in this study, and the objective response rate (CR þ PR) were similar: 41% (n ¼ 9) and 45% (n ¼ 10), respectively. For the other target organs of cGVHD, the response rate seemed to be lower, with 27% (n ¼ 3; 2 CR þ 1 PR) for the gastrointestinal tract (n ¼ 11) and 1 PR among the three patients with pulmonary cGVHD. The response rate for oral mucous, joints and ocular cGVHD localizations could not be evaluated in this retrospective study.
DISCUSSION
Extensive or severe cGVHD is a challenge for the transplantation team. The wide use of peripheral stem cells, reduced-intensity conditioning regimens, as well as the high donor and recipient age, explain the importance of an appropriate strategy to treat this complication. For several years, the Seattle scheme has been used to classify the extension of cGVHD. 20 However, this classification cannot be used to segregate patients with extensive cGVHD. Recently, a NIH-sponsored consensus conference proposed a new standard for the diagnosis, staging and response to therapy. 16, 18 In this consensus, cGVHD was classified as 'mild', 'moderate' and 'severe' based on the extension and severity of individual organ involvement and functional impairment. Although the population analyzed was heterogeneous in terms of hematological malignancies, conditioning regimens and sources of hematopoietic stem cells, most patients had severe refractory and highly pretreated cGVHD. In this population, the TLI in chronic GVHD R Devillier et al global response rate of 45% at 3 months was encouraging. Thirteen of the fourteen responsive patients showed a response 3 months after TLI. There was only one late response at 6 months. Moreover, a response 3 months after TLI significantly predicted a lower 5-year GVHD-related mortality of 14% vs 42% for nonresponding patients (P ¼ 0.038). These results were based on the assumption that 3 months after TLI could be considered to be a viable time point for evaluation of the response. However, certain forms of cGVHD (for example, lung fibrosis, skin sclerosis) are known to be associated with long-term symptoms and after effects, and problematic evaluations of response. A longer time point for evaluation of response could be pertinent in these few cases.
The optimal management of refractory cGVHD is not known. This could be explained (at least in part) by the complexity of the balance between the efficacy and tolerance of most immunosuppressive agents. To expose patients to the side effects of ineffective drugs is a risk of a multi-agent strategy in the treatment of refractory cGVHD. Moreover, a retrospective study showed that multi-agent treatment leads to impairment in quality of life. 21 To discontinue administration of some immunosuppressive agents could be considered to be the main goal. Here, we considered corticosteroid sparing as a strong surrogate endpoint. We reported 5 (29%) of 17 nonresponsive patients who reduced the amount of immunosuppressive drugs taken. This suggested a benefit of TLI that was beyond the criteria of an objective response. However, this reduction in immunosuppressive doses could also been considered to be a late effect of the long duration of daily treatments more than to TLI.
In a similar retrospective trial with thoracoabdominal irradiation in 41 patients with refractory cGVHD, 22 the cumulative response was 84%, and the best response was observed with regard to fasciitis (79%), oral GVHD lesions (73%), skin (67%) and the ocular system (67%). Fifty-seven percent of patients had a 50% reduction of their daily dose of corticosteroids. Ten-year survival from thoracoabdominal irradiation was 57%. A survey on second-line treatment of cGVHD showed that thoracoabdominal irradiation was used occasionally only in three centers among 30 transplant centers carrying out allogeneic hematopoietic SCT. 23 More frequently, second-line therapies comprise new agents such as targeted therapy (rituximab, 24 27 ), with an objective response rate ranging from 20 and 70%. However, use of these treatments is limited by their side effects, which carry a high risk of severe immunodeficiency for multitreated refractory patients. Moreover, the duration of such treatments is often long. This can lead to high morbidity (especially for infectious diseases). We did not observe adverse side effects after TLI. TLI could be a viable alternative for secondline therapy for severe cGVHD. Moreover, patients with TLIrefractory GVHD could receive, as a second treatment, other 
